



FCI/GB 2004/ 0 0 4 0 0 7

GB04/4934



INVESTOR IN PEOPLE

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales

NP10 8QQ	
REC'D 28 DEC 2004	
WIPO	PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.


Signed

Stephen Hordley

Dated

9 December 2004

BEST AVAILABLE COPY



1/77
25NOV03 0854692-1 D029341
P01/7700 0.00-0327331.5

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference 101120-1 GB

2. Patent application number
(The Patent Office will fill in this part) 0327331.5

3. Full name, address and postcode of the or of each applicant (underline all surnames)
AstraZeneca AB
SE-151 85 Sodertalje
Sweden

Patents ADP number (if you know it) 7822448003

If the applicant is a corporate body, give the country/state of its incorporation Sweden

4. Title of the invention
THERAPEUTIC AGENTS

5. Name of your agent (if you have one) Thomas Kerr MILLER
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)
AstraZeneca
Global Intellectual Property
PO Box 272
Mereside, Alderley Park
Macclesfield,
Cheshire SK10 4GR

Patents ADP number (if you know it) 8179707002

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description 25

Claim(s)

Abstract 1

Drawing(s)

SN

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

Kevin Bill

Date 24/11/03

Kevin Bill - Authorised Signatory

12. Name and daytime telephone number of person to contact in the United Kingdom

Jennifer Bennett - 01625 230148

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

THERAPEUTIC AGENTS

Field of invention

The present invention relates to certain compounds of formula I, to processes for preparing such compounds, to their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.


Background of the invention

It is known that certain CB₁ modulators (known as antagonists or inverse agonists) are useful in the treatment of obesity, psychiatric and neurological disorders (WO01/70700 and EP 656354). However, there is a need for CB₁ modulators with improved physicochemical properties and/or DMPK properties and/or pharmacodynamic properties.

2,3-Diphenyl- 5H-pyrrolo[3,4-b]pyrazine-5,7(6H)-dione is disclosed in Agricultural and Biological Chemistry (1981), 45(9), 2129-30 and in Journal of Polymer Science, Polymer Chemistry Edition (1971), 9(4), 1117-38.

Description of the invention

The invention relates to a compound of formula (I)



and pharmaceutically acceptable salts thereof, in which

R¹ and R² independently represent phenyl, thienyl, pyridyl, C₁₋₁₀alkyl, C₁₋₁₀alkoxy or C₃₋₁₅cycloalkyl ;

R^3 represents a C_{1-15} alkyl group, C_{3-15} cycloalkyl, a phenyl C_{1-4} alkyl group, a heteroaryl C_{1-4} alkyl group, or a group $R^4(CH_2)_n$ in which R^4 represents a saturated or partially unsaturated 5 to 8 membered heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen or sulphur and n is 0, 1, 2, 3 or 4;

5 X and Y independently represent O or S;


m and n independently represent 0 or 1;

wherein each of R^1 , R^2 , R^3 and R^4 is optionally substituted by one, two or three groups represented by Z wherein Z represents a C_{1-6} alkyl group optionally substituted by one or more fluoro, a C_{1-6} alkoxy group optionally substituted by one or more fluoro, hydroxy,

10 halo, trifluoromethylsulphonyl, benzyl, nitro, amino, mono or di C_{1-4} alkylamino, mono or di C_{1-3} alkylamido, C_{1-3} alkylsulphonyl, C_{1-6} alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3} alkyl carbamoyl, sulphamoyl or acetyl.

A particular group of compounds of formula I is represented by formula IA

15



IA

in which R^1 , R^2 and R^3 are as previously defined.

It will be understood that where a substituent Z is present in more than one group that these substituents are independently selected and may be the same or different.

20

The term C_{3-15} cycloalkyl includes monocyclic, bicyclic, tricyclic and spiro systems for example, cyclopentyl, cyclohexyl and adamantyl.

25 The term heteroaryl means an aromatic 5-, 6-, or 7-membered monocyclic ring or a 9- or 10-membered bicyclic ring, with up to five ring heteroatoms selected from oxygen,

nitrogen and sulfur. Suitable aromatic heteroaryl groups include, for example furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, 1,3,5-triazenyl, benzofuranyl, indolyl, benzothienyl, benzoxazolyl, benzimidazolyl, benzothiazolyl, indazolyl, benzofurazanyl, quinolyl, isoquinolyl, quinazolinyl, quinoxalyl, cinnolyl or naphthyridinyl. Preferably furyl, pyrrolyl, thienyl, oxazolyl, isoxazolyl, imidazolyl, pyrazolyl, oxazolyl thiazolyl, isothiazolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl or 1,3,5-triazenyl and more preferably pyrrolyl, thienyl, imidazolyl, oxazolyl or pyridyl.

Suitable saturated or partially unsaturated 5 to 8 membered heterocyclic groups containing one or more heteroatoms selected from nitrogen, oxygen or sulphur include, for example oxiranyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, 2,3-dihydro-1,3-thiazolyl, 1,3-thiazolidinyl, pyrrolinyl, pyrrolidinyl, morpholinyl, tetrahydro-1,4-thiazinyl, 1-oxotetrahydrothienyl, 1,1-dioxotetrahydro-1,4-thiazinyl, piperidinyl, homopiperidinyl, piperazinyl, homopiperazinyl, dihydropyridinyl, tetrahydropyridinyl, dihydropyrimidinyl or tetrahydropyrimidinyl, preferably tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl, morpholinyl, piperidinyl or piperazinyl, more preferably tetrahydrofuran-3-yl, tetrahydropyran-4-yl, pyrrolidin-3-yl, morpholino, piperidino, piperidin-4-yl or piperazin-1-yl.

Particularly Z represents halo, trifluoromethyl, trifluoromethylthio, difluoromethoxy or trifluoromethoxy.

Further values of R^1 , R^2 , R^3 , and R^4 in compounds of formula I and compounds of formula IA now follow. It will be understood that such values may be used where appropriate with any of the definitions, claims or embodiments defined hereinbefore or hereinafter.

R¹ and R² independently represent phenyl optionally substituted independently by one or two halo. Particularly R¹ and R² are identical. More particularly R¹ and R² each represent 4-chlorophenyl.

5 R³ represents a phenylC₁₋₄alkyl, pyridylC₁₋₄alkyl, a C₁₋₆alkyl group, piperidino, morpholino, pyrrolidino wherein the phenyl ring is optionally substituted by halo and the pyridyl ring is optionally substituted by one or more of the following :halo, a C₁₋₆alkyl group (optionally substituted by one or more fluoro for example trifluoromethyl), or a C₁₋₆alkoxy group (optionally substituted by one or more fluoro for example difluoromethoxy or trifluoromethoxy). Particularly R³ represents benzyl, halobenzyl, pyridylmethyl, 10 piperidino or a C₃₋₄alkyl group. More particularly R³ represents 4-fluorobenzyl, 4-pyridylmethyl, piperidino or *tert*-butyl.

X and Y both present O.

15

m and n are both 0.

In one group of compounds of formula I R¹ and R² independently represent phenyl optionally substituted independently by one or two chloro, R³ represents benzyl, 20 halobenzyl, pyridylmethyl, piperidino or a C₃₋₄alkyl group, X and Y are both O and m and n are both 0.

"Pharmaceutically acceptable salt", where such salts are possible, includes both pharmaceutically acceptable acid and base addition salts. A suitable pharmaceutically acceptable salt of a compound of Formula I is, for example, an acid-addition salt of a 25 compound of Formula I which is sufficiently basic, for example an acid-addition salt with an inorganic or organic acid such as hydrochloric, hydrobromic, sulphuric, trifluoroacetic, citric or maleic acid; or, for example a salt of a compound of Formula I which is sufficiently acidic; for example an alkali or alkaline earth metal salt such as a sodium, 30 calcium or magnesium salt, or an ammonium salt, or a salt with an organic base such as

methyllamine, dimethylamine, trimethylamine, piperidine, morpholine or tris-(2-hydroxyethyl)amine.

Throughout the specification and the appended claims, a given chemical formula or name
5 shall encompass all stereo and optical isomers and racemates thereof as well as mixtures in different proportions of the separate enantiomers, where such isomers and enantiomers exist, as well as pharmaceutically acceptable salts thereof and solvates thereof such as for instance hydrates. Isomers may be separated using conventional techniques, e.g. chromatography or fractional crystallisation. The enantiomers may be isolated by
10 separation of racemate for example by fractional crystallisation, resolution or HPLC. The diastereomers may be isolated by separation of isomer mixtures for instance by fractional crystallisation, HPLC or flash chromatography. Alternatively the stereoisomers may be made by chiral synthesis from chiral starting materials under conditions which will not cause racemisation or epimerisation, or by derivatisation, with a chiral reagent. All
15 stereoisomers are included within the scope of the invention. All tautomers, where possible, are included within the scope of the invention.

The following definitions shall apply throughout the specification and the appended claims.

20 Unless otherwise stated or indicated, the term "alkyl" denotes either a straight or branched alkyl group. Examples of said alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl and t-butyl. Preferred alkyl groups are methyl, ethyl, propyl, isopropyl and tertiary butyl.

25 Unless otherwise stated or indicated, the term "alkoxy" denotes a group O-alkyl, wherein alkyl is as defined above.

Unless otherwise stated or indicated, the term "halogen" shall mean fluorine, chlorine,
30 bromine or iodine.


Specific compounds of the invention are one or more of the following:

- 2,3-bis(4-chlorophenyl)-6-(4-fluorobenzyl)-5H-pyrrolo[3,4-b]pyrazine-5,7(6H)-dione;
 2,3-bis(4-chlorophenyl)-6-(pyridin-4-ylmethyl)-5H-pyrrolo[3,4-b]pyrazine-5,7(6H)-dione;
 2,3-bis(4-chlorophenyl)-6-piperidin-1-yl-5H-pyrrolo[3,4-b]pyrazine-5,7(6H)-dione; or
 5 6-*tert*-butyl-2,3-bis(4-chlorophenyl)-5H-pyrrolo[3,4-b]pyrazine-5,7(6H)-dione
 as well as pharmaceutically acceptable salts thereof.

Methods of preparation

- 10 The compounds of the invention may be prepared as outlined below according to any of the following methods. However, the invention is not limited to these methods, the compounds may also be prepared as described for structurally related compounds in the prior art.
- 15 Compounds of formula I in which m and n are each 0 and X and Y are both O are prepared by reacting a compound of formula II with a dehydrating agent for example oxalyl chloride optionally in the presence of a solvent for the compound of formula II at a temperature in the range of 0-100°C.

Synthetic Scheme



Compounds of formula I in which either X or Y or both X and Y are S may be prepared by reacting a compound of formula I in which X and Y are both O with an appropriate molar amount of Lawesson's reagent by methods known to those skilled in the art.

5 Compounds of formula I in which either of n and m is 1 or both are 1 may be prepared by oxidising a compound of formula I in which n and m are both 0 with an appropriate molar quantity of oxidising agent for example a peroxide e.g. hydrogen peroxide or sulphuric peroxide.

10 Certain compounds of formula II and III are believed to be novel and form part of the present invention.

Pharmaceutical preparations

15 The compounds of the invention will normally be administered via the oral, parenteral, intravenous, intramuscular, subcutaneous or in other injectable ways, buccal, rectal, vaginal, transdermal and/or nasal route and/or via inhalation, in the form of pharmaceutical preparations comprising the active ingredient or a pharmaceutically acceptable addition salt, in a pharmaceutically acceptable dosage form. Depending upon the disorder and
20 patient to be treated and the route of administration, the compositions may be administered at varying doses.

Suitable daily doses of the compounds of the invention in the therapeutic treatment of humans are about 0.001-10 mg/kg body weight, preferably 0.01-1 mg/kg body weight.

25

Oral formulations are preferred particularly tablets or capsules which may be formulated by methods known to those skilled in the art to provide doses of the active compound in the range of 0.5mg to 500mg for example 1 mg, 3 mg, 5 mg, 10 mg, 25mg, 50mg, 100mg and 250mg.

30

According to a further aspect of the invention there is also provided a pharmaceutical formulation including any of the compounds of the invention, or pharmaceutically acceptable derivatives thereof, in admixture with pharmaceutically acceptable adjuvants, diluents and/or carriers.

5

Pharmacological properties

The compounds of formula (I) are useful for the treatment of obesity, psychiatric disorders such as psychotic disorders, schizophrenia, bipolar disorders, anxiety, anxio-depressive disorders, depression, cognitive disorders, memory disorders, obsessive-compulsive disorders, anorexia, bulimia, attention disorders like ADHD, epilepsy, and related conditions, and neurological disorders such as dementia, neurological disorders (e.g. Multiple Sclerosis), Raynaud's syndrome, Parkinson's disease, Huntington's chorea and Alzheimer's disease. The compounds are also potentially useful for the treatment of immune, cardiovascular, reproductive and endocrine disorders, septic shock and diseases related to the respiratory and gastrointestinal systems (e.g. diarrhea). The compounds are also potentially useful as agents in treatment of extended abuse, addiction and/or relapse indications, e.g. treating drug (nicotine, ethanol, cocaine, opiates, etc) dependence and/or treating drug (nicotine, ethanol, cocaine, opiates, etc) withdrawal symptoms. The compounds may also eliminate the increase in weight which normally accompanies the cessation of smoking.

25

In another aspect the present invention provides a compound of formula I as previously defined for use as a medicament.

30

In a further aspect the present invention provides the use of a compound of formula I in the preparation of a medicament for the treatment or prophylaxis of obesity, psychiatric disorders such as psychotic disorders, schizophrenia, bipolar disorders, anxiety, anxio-depressive disorders, depression, cognitive disorders, memory disorders, obsessive-compulsive disorders, anorexia, bulimia, attention disorders like ADHD, epilepsy, and related conditions, neurological disorders such as dementia, neurological disorders (e.g. Multiple Sclerosis), Parkinson's Disease, Huntington's Chorea and Alzheimer's Disease,

immune, cardiovascular, reproductive and endocrine disorders, septic shock, diseases related to the respiratory and gastrointestinal systems (e.g. diarrhea), and extended abuse, addiction and/or relapse indications, e.g. treating drug (nicotine, ethanol, cocaine, opiates, etc) dependence and/or treating drug (nicotine, ethanol, cocaine, opiates, etc) withdrawal symptoms.

In a still further aspect the present invention provides a method of treating obesity, psychiatric disorders such as psychotic disorders such as schizophrenia and bipolar disorders, anxiety, anxio-depressive disorders, depression, cognitive disorders, memory disorders, obsessive-compulsive disorders, anorexia, bulimia, attention disorders like ADHD, epilepsy, and related conditions, neurological disorders such as dementia, neurological disorders (e.g. Multiple Sclerosis), Parkinson's Disease, Huntington's Chorea and Alzheimer's Disease, immune, cardiovascular, reproductive and endocrine disorders, septic shock, diseases related to the respiratory and gastrointestinal systems (e.g. diarrhea), and extended abuse, addiction and/or relapse indications, e.g. treating drug (nicotine, ethanol, cocaine, opiates, etc) dependence and/or treating drug (nicotine, ethanol, cocaine, opiates, etc) withdrawal symptoms comprising administering a pharmacologically effective amount of a compound of formula I to a patient in need thereof.

The compounds of the present invention are particularly suitable for the treatment of obesity, e.g. by reduction of appetite and body weight, maintenance of weight reduction and prevention of rebound.

Combination Therapy

The compounds of the invention may be combined with another therapeutic agent that is useful in the treatment of disorders associated with the development and progress of obesity such as hypertension, hyperlipidaemias, dyslipidaemias, diabetes and atherosclerosis. For example, a compound of the present invention may be used in combination with a compound that affects thermogenesis, lipolysis, fat absorption, satiety, or gut motility. The compounds of the invention may be combined with another therapeutic agent that decreases the ratio of LDL:HDL or an agent that causes a decrease in circulating levels of LDL-cholesterol. In patients with diabetes mellitus the compounds of the

invention may also be combined with therapeutic agents used to treat complications related to micro-angiopathies.

The compounds of the invention may be used alongside other therapies for the treatment of obesity and its associated complications the metabolic syndrome and type 2 diabetes, these include biguanide drugs, insulin (synthetic insulin analogues) and oral antihyperglycemics (these are divided into prandial glucose regulators and alpha-glucosidase inhibitors).

In another aspect of the invention, the compound of formula I, or a pharmaceutically acceptable salt thereof may be administered in association with a PPAR modulating agent. PPAR modulating agents include but are not limited to a PPAR alpha and/or gamma agonist, or pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof. Suitable PPAR alpha and/or gamma agonists, pharmaceutically acceptable salts, solvates, solvates of such salts or prodrugs thereof are well known in the art.

In addition the combination of the invention may be used in conjunction with a sulfonylurea. The present invention also includes a compound of the present invention in combination with a cholesterol-lowering agent. The cholesterol-lowering agents referred to in this application include but are not limited to inhibitors of HMG-CoA reductase (3-hydroxy-3-methylglutaryl coenzyme A reductase). Suitably the HMG-CoA reductase inhibitor is a statin

In the present application, the term "cholesterol-lowering agent" also includes chemical modifications of the HMG-CoA reductase inhibitors, such as esters, prodrugs and metabolites, whether active or inactive.

The present invention also includes a compound of the present invention in combination with an inhibitor of the ileal bile acid transport system (IBAT inhibitor). The present invention also includes a compound of the present invention in combination with a bile acid binding resin.

The present invention also includes a compound of the present invention in combination with a bile acid sequestering agent, for example colestipol or cholestyramine or cholestagel

According to an additional further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration one or more of the following agents selected from:

5 a CETP (cholesteryl ester transfer protein) inhibitor;

a cholesterol absorption antagonist;

a MTP (microsomal transfer protein) inhibitor ;

a nicotinic acid derivative, including slow release and combination products;

10 a phytosterol compound ;

probucol;

an anti-coagulant;

an omega-3 fatty acid ;

another anti-obesity compound;

15 an antihypertensive compound for example an angiotensin converting enzyme (ACE) inhibitor, an angiotensin II receptor antagonist, an adrenergic blocker, an alpha adrenergic blocker, a beta adrenergic blocker, a mixed alpha/beta adrenergic blocker, an adrenergic stimulant, calcium channel blocker, an AT-1 blocker, a saluretic, a diuretic or a vasodilator;

20 a Melanin concentrating hormone (MCH) antagonist;

a PDK inhibitor; or

modulators of nuclear receptors for example LXR, FXR, RXR, and RORalpha;

an SSRI;

a serotonin antagonist;

25 or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.

Therefore in an additional feature of the invention, there is provided a method for for the treatment of obesity and its associated complications in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof in

simultaneous, sequential or separate administration with an effective amount of a compound from one of the other classes of compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

5

Therefore in an additional feature of the invention, there is provided a method of treating hyperlipidemic conditions in a warm-blooded animal, such as man, in need of such treatment which comprises administering to said animal an effective amount of a

compound of formula I, or a pharmaceutically acceptable salt thereof in simultaneous, sequential or separate administration with an effective amount of a compound from one of the other classes of compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

15

According to a further aspect of the invention there is provided a pharmaceutical composition which comprises a compound of formula I, or a pharmaceutically acceptable salt thereof, and a compound from one of the other classes of compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in association with a pharmaceutically acceptable diluent or carrier.

20

According to a further aspect of the present invention there is provided a kit comprising a compound of formula I, or a pharmaceutically acceptable salt thereof, and a compound from one of the other classes of compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof.

25

According to a further aspect of the present invention there is provided a kit comprising:
a) a compound of formula I, or a pharmaceutically acceptable salt thereof, in a first unit dosage form;

b) a compound from one of the other classes of compounds described in this combination section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof; in a second unit dosage form; and

30

c) container means for containing said first and second dosage forms.

According to a further aspect of the present invention there is provided a kit comprising:

a) a compound of formula I, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable diluent or carrier, in a first unit dosage form;

b) a compound from one of the other classes of compounds described in this combination

section or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in a second unit dosage form; and

c) container means for containing said first and second dosage forms.

According to another feature of the invention there is provided the use of a compound of

the formula I, or a pharmaceutically acceptable salt thereof, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment of obesity and its associated complications in a warm-blooded animal, such as man.

According to another feature of the invention there is provided the use of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, in the manufacture of a medicament for use in the treatment of hyperlipidaemic conditions in a warm-blooded animal, such as man.

According to a further aspect of the present invention there is provided a combination treatment comprising the administration of an effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, optionally together with a pharmaceutically acceptable diluent or carrier, with the simultaneous, sequential or separate administration of an effective amount of one of the other compounds described in this combination section, or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, optionally together with a pharmaceutically acceptable diluent or carrier to a warm-blooded animal, such as man in need of such therapeutic treatment.

Furthermore, a compound of the invention may also be combined with therapeutic agents that are useful in the treatment of disorders or conditions associated with obesity (such as

type II diabetes, metabolic syndrome, dyslipidemia, impaired glucose tolerance, hypertension, coronary heart disease, non-alcoholic steatorrheic hepatitis, osteoarthritis and some cancers) and psychiatric and neurological conditions.

5 Pharmacological Activity

Compounds of the present invention are active against the receptor product of the CB1 gene. The affinity of the compounds of the invention for central cannabinoid receptors is demonstrable in methods described in Devane et al, Molecular Pharmacology, 1988, 34,605 or those described in WO01/70700 or EP 656354. Alternatively the assay may be

10 performed as follows.

10 μ g of membranes prepared from cells stably transfected with the CB1 gene were suspended in 200 μ l of 100mM NaCl, 5mM MgCl₂, 1mM EDTA, 50mM HEPES (pH 7.4), 1mM DTT, 0.1% BSA and 100 μ M GDP. To this was added an EC80 concentration of agonist (CP55940), the required concentration of test compound and 0.1 μ Ci [³⁵S]-GTP γ S.

15 The reaction was allowed to proceed at 30°C for 45 min. Samples were then transferred on to GF/B filters using a cell harvester and washed with wash buffer (50mM Tris (pH 7.4), 5mM MgCl₂, 50mM NaCl). Filters were then covered with scintillant and counted for the amount of [³⁵S]-GTP γ S retained by the filter.

Activity is measured in the absence of all ligands (minimum activity) or in the presence of
20 an EC80 concentration of CP55940 (maximum activity). These activities are set as 0% and 100% activity respectively. At various concentrations of novel ligand, activity is calculated as a percentage of the maximum activity and plotted. The data are fitted using the equation $y=A+((B-A)/(1+((C/x)^{1/D})))$ and the IC₅₀ value determined as the concentration required to give half maximal inhibition of GTP γ S binding under the
25 conditions used.

The compounds of the present invention are active at the CB1 receptor (IC₅₀ <1 micromolar). Most preferred compounds have IC₅₀ <200 nanomolar.

The compounds of the invention are believed to be selective CB1 antagonists.

ExamplesAbbreviations

DCM - dichloromethane

5 DMF - dimethylformamide

DMAP - 4-dimethylaminopyridine

EDC - 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide

TEA - triethylamine

TFA - trifluoroacetic acid

10 DMSO - dimethyl sulfoxide

DEA - Diethylamine

PCC - Pyridinium chlorochromate

PyBOP - benzotriazol-1-yl-oxytri-pyrrolidinophosphonium hexafluorophosphate

HBTU - *O*-Benzotriazol-1-yl-*N,N,N',N'*-tetramethyluronium Hexafluorophosphate

15 DAST - (diethyl amino)sulphur trifluoride

DIEA - *N,N*-diisopropylethylamine

t triplet

s singlet

d doublet

20 q quartet

qvint quintet

m multiplet

br broad

bs broad singlet

25 dm doublet of multiplet

bt broad triplet

dd doublet of doublet

General Experimental Procedures

Mass spectra were recorded on either a Micromass ZQ single quadrupole or a Micromass

30 LCZ single quadrupole mass spectrometer both equipped with a pneumatically assisted
electrospray interface (LC-MS). ¹H NMR measurements were performed on either a

Varian Mercury 300 or a Varian Inova 500, operating at ^1H frequencies of 300 and 500 MHz respectively. Chemical shifts are given in ppm with CDCl_3 as internal standard.

CDCl_3 is used as the solvent for NMR unless otherwise stated. Purification was performed on a semipreparative HPLC with a mass triggered fraction collector, Shimadzu QP 8000 single quadrupole mass spectrometer equipped with 19 x 100 mm C8 column. The mobile phase used was, if nothing else is stated, acetonitrile and buffer (0.1 M NH_4Ac :acetonitrile 95:5).


For isolation of isomers, a Kromasil CN E9344 (250 x 20 mm i.d.) column was used.

Heptane:ethyl acetate:DEA 95:5:0.1 was used as mobile phase (1 ml/min). Fraction collection was guided using a UV-detector (330 nm).

Examples of the Invention

Example 1


Step A 5,6-bis(4-chlorophenyl)pyrazine-2,3-dicarbonitrile



A mixture of 1,2-bis(4-chlorophenyl)ethane-1,2-dione, (20 g, 71.65 mmol), diaminomaleonitrile (8.5 g, 78.82 mmol) and acetic acid (6 ml) in ethanol (140 ml) and water (93 ml) was heated at 75 °C overnight. The reaction mixture was cooled, and water was added. The precipitate was filtered and washed with ethanol and then ether. The crude product was dissolved in DCM and treated with activated charcoal, then filtered through celite. The solid was recrystallized from DCM/ethanol to give the title compound (17.3 g, 69%) as a solid.

^1H NMR (400 MHz) δ 7.49 (d, 4H), 7.38 (d, 4H).


Step B 5,6-bis(4-chlorophenyl)pyrazine-2,3-dicarboxylic acid



To a suspension of 5,6-bis(4-chlorophenyl)pyrazine-2,3-dicarbonitrile, Example 1, Step A (16.3 g, 46.28 mmol) and KOH (26 g, 463 mmol) in water (84 ml) was added hydrogen peroxide (35%, 19 ml) followed by a few drops of nonanol to reduce foaming. The reaction mixture was boiled under reflux for 2h, cooled and washed with ether and acidified to pH 4 with 2M HCl. The precipitate was filtered, washed with water and dried under reduced pressure to give the crude product which was esterified by refluxing in hydrogen chloride/methanol (100 ml) followed by HPLC purification, giving 12.85 g of the methyl ester. The resulting methyl ester in acetonitrile (140 ml) and water (90 ml) was treated with lithium hydroxide (2.95 g, 0.123 mmol) at ambient temperature for 1.5 h. The acetonitrile was removed under reduced pressure and the aqueous solution was washed with diethyl ether. Acidification with hydrochloric acid (2M) gave the title compound (11.8 g, 66% mmol) as a pale yellow solid which was isolated by filtration.

¹H NMR (400 MHz) δ 7.51 (d, 4H), 7.41 (d, 4H). MS m/z 389, 391 (M+H)⁺.


Step C 2,3-bis(4-chlorophenyl)furo[3,4-b]pyrazine-5,7-dione



A mixture of 5,6-bis(4-chlorophenyl)pyrazine-2,3-dicarboxylic acid, Example 1, Step B (6.7 g, 17.30 mmol) and acetyl chloride (20 ml) was boiled under reflux overnight. The excess of acetyl chloride was removed under reduced pressure to give the title compound (6.2 g, 97%) as a solid.

¹H NMR (400 MHz) δ 7.51 (d, 4H), 7.41 (d, 4H).

Step D 5,6-bis(4-chlorophenyl)-3-[[4-(4-fluorobenzyl)amino]carbonyl]pyrazine-2-carboxylic acid:




(4-Fluorobenzyl)amine (202 mg, 1.61 mmol) was mixed with 2,3-bis(4-chlorophenyl)furo[3,4-*b*]pyrazine-5,7-dione Ex. 1, Step C (544 mg, 1.47 mmol) in acetonitrile (10 ml). The reaction mixture was left at room temperature for 60 h.

Evaporation followed by purification by HPLC gave the pure compound (700 mg, 96%).

¹H NMR (500 MHz, CD₃OD) δ 7.55-7.46 (m, 4H), 7.46-7.39 (m, 2H), 7.39-7.34 (m, 4H), 7.08-7.01 (m, 2H) 4.60 (s, 2H).

MS *m/z* calcd for [C₂₅H₁₇Cl₂N₃O₃F]⁺ 496.0631, found 496.0643 (M+H)⁺

Step E 2,3-bis(4-chlorophenyl)-6-(4-fluorobenzyl)-5H-pyrrolo[3,4-*b*]pyrazine-5,7(6H)-dione:




5,6-Bis(4-chlorophenyl)-3-[[4-(4-fluorobenzyl)amino]carbonyl]pyrazine-2-carboxylic acid, Ex.1, Step D (220 mg, 0.443 mmol) was dissolved in methylene chloride (5 ml). DMF (20 microlitres) was added and then oxalyl chloride (1 ml). After 1 hour at room temperature the solvent was removed in vacuo and the residue was purified by preparative HPLC to give the title compound (156 mg, 74%).

^1H NMR (500 MHz, CDCl_3) δ 7.52-7.42 (m, 6H), 7.36-7.30 (d, 4H), 7.05-6.96 ("t", 2H), 4.95 (s, 2H).

MS m/z calcd for $[\text{C}_{25}\text{H}_{14}\text{Cl}_2\text{FN}_3\text{O}_2]\text{H}^+$ 478.0528, found 478.0559 ($\text{M}+\text{H}$) $^+$.

Example 2

2,3-Bis(4-chlorophenyl)-6-(pyridin-4-ylmethyl)-5H-pyrrolo[3,4-*b*]pyrazine-5,7(6H)-dione



2,3-Bis(4-chlorophenyl)furo[3,4-*b*]pyrazine-5,7-dione, EX1, Step C (214 mg, 0.58 mmol) was dissolved in methylene chloride (3 ml) followed by (pyridin-4-ylmethyl)amine (62 mg, 0.58 mmol). After 5 days at room temperature, DMF (20 microlitres) and thionyl chloride (1 ml) were added. The solvent was removed in vacuo after 1 hour and the residue was purified by preparative HPLC to give the title compound (104 mg, 39%).


^1H NMR (400 MHz, CDCl_3) δ 8.56 (broad s, 2H), 7.45 (d, 4H), 7.35-7.29 (m, 6H), 4.97 (s, 2H).

MS m/z calcd for $[C_{24}H_{14}Cl_2N_4O_2]H^+$ 461.0572, found 461.0585 ($M+H$) $^+$

Example-3

Step A 5,6-bis(4-chlorophenyl)-3-[(piperidin-1-ylamino)carbonyl]pyrazine-2-carboxylic acid:

5 acid:




A solution of piperidin-1-amine (292 mg, 2.91 mmol) in acetonitrile (10 ml) was added to a solution of 2,3-bis(4-chlorophenyl)furo[3,4-*b*]pyrazine-5,7-dione, Ex1, Step C (1.03 g, 2.78 mmol) in acetonitrile (10 ml). After 2 hours the solvent was removed in vacuo and the title compound could be isolated by crystallization from acetonitrile. The yield was 807 mg (62%).

1H NMR (400 MHz) δ 7.55 (d, 2H), 7.46 (d, 2H), 7.37 (d, 2H), 7.31 (d, 2H), 3.05-2.97 (m, 4H), 1.84-1.77 (m, 4H), 1.54-1.46 (m, 2H).

15 MS m/z calcd for $[C_{23}H_{21}Cl_2N_4O_3]H^+$ 471.0991, found 471.0994 ($M+H$) $^+$.

Step B 2,3-bis(4-chlorophenyl)-6-piperidin-1-yl-5H-pyrrolo[3,4-*b*]pyrazine-5,7(6H)-dione:



20 Oxalyl chloride (0.4 ml) was added to 5,6-bis(4-chlorophenyl)-3-[(piperidin-1-ylamino)carbonyl]pyrazine-2-carboxylic acid (229 mg, 0.486 mmol) in methylene chloride (10 ml). After 10 minutes water was added and then sodium carbonate solution.


The organic phase was washed with water and the solvent was evaporated. The product was isolated by crystallisation from methylene chloride/hexane (92 mg, 42%).

^1H NMR (400 MHz) δ 7.47 (d, 4H), 7.34 (d, 4H), 3.41-3.36 (m, 4H), 1.84-1.76 (m, 4H), 1.60-1.50 (m, 2H).

MS m/z calcd for $[\text{C}_{23}\text{H}_{18}\text{Cl}_2\text{N}_4\text{O}_2]\text{H}^+$ 453.0918, found 453.0885 $(\text{M}+\text{H})^+$.


Example 4

STEP A 3-[(*tert*-butylamino)carbonyl]-5,6-bis(4-chlorophenyl)pyrazine-2-carboxylic acid



To a solution of 2,3-bis(4-chlorophenyl)furo[3,4-*b*]pyrazine-5,7-dione, Ex.1, stepC (500 mg, 1.35 mmol) in acetonitrile (10 ml) was added *tert*-butylamine (99 mg, 1.35 mmol). The reaction mixture was stirred in room temperature for 1h 15min to give the subtitle compound. ^1H NMR (400 MHz) δ 7.46-7.41 (m, 4H), 7.38-7.34 (m, 4H), 1.41 (s, 9H). MS m/z 444 $(\text{M}+\text{H})^+$.

20 Step B 6-*tert*-butyl-2,3-bis(4-chlorophenyl)-5H-pyrrolo[3,4-*b*]pyrazine-5,7(6H)-dione




To a solution of 3-[(*tert*-butylamino)carbonyl]-5,6-bis(4-chlorophenyl)pyrazine-2-carboxylic, Ex. 4, Step A (100 mg, 0.23mmol) in methylene chloride (5 ml) were added oxalyl chloride (2.5 ml) and a few drops of *N,N*-dimethylformamide. The reaction mixture was stirred in room temperature for 2 hours. The mixture was then filtered through silica and preparatory HPLC gave the title compound as a solid. ^1H NMR (400 MHz) δ 7.45 (d, 4H), 7.32 (d, 4H), 1.75 (s, 9H).

MS m/z 426 ($\text{M}+\text{H}^+$).

Claims

1. A compound of formula (I)



and pharmaceutically acceptable salts thereof, in which

R^1 and R^2 independently represent phenyl, thienyl, pyridyl, C_{1-10} alkyl, C_{1-10} alkoxy or C_{3-15} cycloalkyl ;

R^3 represents a C_{1-15} alkyl group, C_{3-15} cycloalkyl, a phenyl C_{1-4} alkyl group, a heteroaryl C_{1-4} alkyl group, or a group $R^4(CH_2)_n$ in which R^4 represents a saturated or partially unsaturated 5 to 8 membered heterocyclic group containing one or more heteroatoms selected from nitrogen, oxygen or sulphur and n is 0, 1, 2, 3 or 4;


X and Y independently represent O or S;

m and n independently represent 0 or 1;

wherein each of R^1 , R^2 , R^3 and R^4 is optionally substituted by one, two or three groups represented by Z wherein Z represents a C_{1-6} alkyl group optionally substituted by one or more fluoro, a C_{1-6} alkoxy group optionally substituted by one or more fluoro, hydroxy, halo, trifluoromethylsulphonyl, benzyl, nitro, amino, mono or di C_{1-4} alkylamino, mono or di C_{1-3} alkylamido, C_{1-3} alkylsulphonyl, C_{1-6} alkoxycarbonyl, carboxy, cyano, carbamoyl,

mono or di C_{1-3} alkyl carbamoyl, sulphamoyl or acetyl.

2. A compound of formula (IA)



IA

and pharmaceutically acceptable salts thereof, in which

5 R^1 and R^2 independently represent phenyl, thienyl, pyridyl, C_{1-10} alkyl, C_{1-10} alkoxy or C_{3-15} cycloalkyl ;

R^3 represents a C_{1-15} alkyl group, C_{3-15} cycloalkyl, a phenyl C_{1-4} alkyl group, a heteroaryl C_{1-4} alkyl group, or a group $R^4(CH_2)_n$ in which R^4 represents a saturated or partially unsaturated 5 to 8 membered heterocyclic group containing one or more heteroatoms

10 : selected from nitrogen, oxygen or sulphur and n is 0, 1, 2, 3 or 4;

X and Y independently represent O or S;

m and n independently represent 0 or 1;

wherein each of R^1 , R^2 , R^3 and R^4 is optionally substituted by one, two or three groups represented by Z wherein Z represents a C_{1-6} alkyl group optionally substituted by one or

15 more fluoro, a C_{1-6} alkoxy group optionally substituted by one or more fluoro, hydroxy, halo, trifluoromethylsulphonyl, benzyl, nitro, amino, mono or di C_{1-4} alkylamino, mono or di C_{1-3} alkylamido, C_{1-3} alkylsulphonyl, C_{1-6} alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C_{1-3} alkyl carbamoyl, sulphamoyl or acetyl.

20

3. A compound of formula I as claimed in either claim 1 or claim 2 for use as a medicament.

4. A pharmaceutical formulation comprising a compound of formula I according either
25 claim 1 or claim 2 and a pharmaceutically acceptable adjuvant, diluent or carrier.

6. Use of a compound of formula I according to either claim 1 or claim 2 in the preparation of a medicament for the treatment or prophylaxis of obesity, psychiatric disorders such as psychotic disorders, schizophrenia and bipolar disorders, anxiety, anxio-depressive disorders, depression, cognitive disorders, memory disorders, obsessive-compulsive disorders, anorexia, bulimia, attention disorders, epilepsy, and related conditions, and neurological disorders such as dementia, neurological disorders, Parkinson's Disease, Huntington's Chorea and Alzheimer's Disease, immune, cardiovascular, reproductive and endocrine disorders, septic shock, diseases related to the respiratory and gastrointestinal systems, and extended abuse, addiction and/or relapse indications.

7. A method of treating obesity, psychiatric disorders, psychotic disorders, schizophrenia and bipolar disorders, anxiety, anxio-depressive disorders, depression, cognitive disorders, memory disorders, obsessive-compulsive disorders, anorexia, bulimia, attention disorders, epilepsy, and related conditions, neurological disorders, neurological disorders, Parkinson's Disease, Huntington's Chorea and Alzheimer's Disease, immune, cardiovascular, reproductive and endocrine disorders, septic shock, diseases related to the respiratory and gastrointestinal system, and extended abuse, addiction and/or relapse indications, comprising administering a pharmacologically effective amount of a compound of formula I according to either claim 1 or claim 2 to a patient in need thereof.

8. A compound as defined in either claim 1 or claim 2 for use in the treatment of obesity.

ABSTRACT

5 The present invention relates to compounds of formula I and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.

PCT/GB2004/004934



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.